Oxycodone for analgesia in children undergoing endoscopic retrograde cholangiopancreatography: a randomized, double-blind, parallel study

Wei Ji, Liping Sun, Yue Huang, Jie Bai, Jijian Zheng, Kan ZhangFrontiers in Pharmacology 2025 · DOI

Abstract

Clinical trial registration: www.chictr.org.cn, identifier ChiCTR2300074473.

Introduction

Endoscopic retrograde cholangiopancreatography (ERCP) is a critical diagnostic and therapeutic tool for pediatric pancreatic and biliary diseases. However, the procedure is invasive and associated with significant post-procedural pain in approximately 28% of children. This pain is primarily visceral, resulting from mechanical stretching and systemic inflammation.

While fentanyl is commonly used in pediatric anesthesia, its efficacy is often limited in visceral pain management as it primarily targets $\mu$-opioid receptors. Furthermore, opioids can induce spasms in the sphincter of Oddi, potentially increasing the risk of post-ERCP pancreatitis. This study investigates whether oxycodone, a $\mu$- and $\kappa$-opioid receptor agonist, provides superior analgesia and a more favorable safety profile compared to fentanyl.

Methods

This single-center, randomized, double-blind, parallel-group study was conducted at Shanghai Children’s Medical Center between September and December 2023. The study enrolled 82 children (ages 2–18) undergoing elective ERCP.

Figure 1: CONSORT flow diagram illustrating participant enrollment, allocation, and analysis.

Participants were randomly assigned to receive either oxycodone (0.2 mg/kg) or fentanyl (2 $\mu$g/kg) during anesthesia induction. Pain was assessed using the Face, Legs, Activity, Cry, Consolability (FLACC) scale for younger children and the Numerical Rating Scale (NRS) for children aged 7 and older. Additionally, serum levels of inflammatory cytokines (IL-6, IL-10, and TNF-$\alpha$) were measured, and adverse events were monitored.

Results

The study found that oxycodone provided significantly better and longer-lasting pain relief than fentanyl. Children in the oxycodone group exhibited lower pain scores at 30 minutes, 6 hours, and 24 hours post-procedure.

Figure 2: Comparison of pain scores (FLACC or NRS) between the oxycodone and fentanyl groups at various time points post-procedure.

Key findings include:

  • Analgesic Superiority: At 6 hours post-procedure, only 36.6% of the oxycodone group reported pain scores $\ge 3$, compared to 61.0% in the fentanyl group ($p = 0.027$).
  • Anti-inflammatory Effects: Oxycodone suppressed the rise of pro-inflammatory cytokines, with fewer children showing elevated IL-6 at 6 hours and TNF-$\alpha$ at 24 hours compared to the fentanyl group.
  • Safety Profile: The incidence of postoperative vomiting was lower in the oxycodone group (14.1%) than in the fentanyl group (24.4%).

Discussion

The superior performance of oxycodone in this context is likely due to its activity at $\kappa$-opioid receptors, which are heavily involved in modulating visceral pain. Additionally, its longer half-life (3–4 hours compared to fentanyl's ~1 hour) ensures a smoother recovery period.

While these results are promising, the study is limited by its single-center design and relatively small sample size. Future multi-center trials with larger cohorts and longer follow-up periods are necessary to confirm these findings and assess the impact on rare complications like post-ERCP pancreatitis. Oxycodone should be considered as part of a multimodal analgesic strategy rather than a standalone treatment.

Conclusion

Oxycodone (0.2 mg/kg) is more effective than fentanyl (2 $\mu$g/kg) for managing post-procedural visceral pain and reducing the systemic inflammatory response in children undergoing ERCP.

Summary updated

Abstract

www.chictr.org.cn, identifier ChiCTR2300074473.
BibTeX
@inproceedings{ji2025oxycodone,
  author = {Wei Ji and Liping Sun and Yue Huang and Jie Bai and Jijian Zheng and Kan Zhang},
  title = {{Oxycodone for analgesia in children undergoing endoscopic retrograde cholangiopancreatography: a randomized, double-blind, parallel study}},
  booktitle = {Frontiers in Pharmacology},
  year = {2025},
  doi = {10.3389/fphar.2024.1515501},
}
Figure